Enochian Biosciences : Investor Presentation – June 2022

Elegant Simplicity: Integrating Diverse Scientific Approaches to Develop Cures

www.enochianbio.com

FORWARD-LOOKING STATEMENTS

Certain statements in this presentation that are not strictly historical in nature, regarding our future operations, strategy, potential regulatory treatment, acceptance or changes, preclinical opportunities or activities, potential commercial sales, or outcomes of later clinical trials, among other topics, are "forward-looking statements" for the purposes of federal securities laws. All statements other than statements of historical fact included in this presentation are forward-looking statements, which may be identified by the use of forward-looking terminology such as "believes," plans," "expects," "aims," "intends" or similar expressions, although not all forward-looking statements contain such identifying words. These forward-looking statements are predictions and expectations of future events based on currently available information and assumptions drawn from currently available information. Be advised that these forward-looking statements are subject to a number of known and unknown risks and uncertainties, many of which are difficult to predict or out of our control, including the success or efficacy of our pipeline, as well as other factors discussed under the heading "Risk Factors" in Enochian's most recently filed Annual Report on Form 10-K and other filings with the SEC. Actual future events, outcomes or results may differ materially from those projected in any of such forward-looking statements due to the occurrence of such uncertainties or the failure of such forward-looking statements' underlying assumptions. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements, expressed or implied, oral or written, are expressly qualified in their entirety by this cautionary statement. Except as otherwise required by applicable law, Enochian undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

2

TECHNOLOGY PLATFORMS

Potential to accelerate and maximize efficiencies/costs in pre-clinical, clinical, regulatory, product development, production, distribution, marketing, reimbursement

Hijack RNA

HIV treatment or cure (HV-31)

HBV cure (HB-01)

Coronavirus Treatment (CV-01)

Tricks viruses to kill

cells they infect

Coronavirus Prophylaxis (CV-11)

Influenza treatment (FL-01)

Influenza prophylaxis (FL-11)

Allogeneic

Cellular

Therapies

HIV Therapeutic Vaccine (HV-12)

HIV Natural Killer and Gamma Delta T-cell Treatment or Cure (HV-21)

Off the Shelf Dendritic Cell Vaccine for Multiple Solid Tumors (DC-11)**

**First target pancreatic cancer